Table 1.
Phase III trials of bevacizumab in ovarian cancer.
| Study | Setting | N | Treatment arm | PFS (median months) | PFS-HR (95% CI) | OS (median months) | OS-HR(95% CI) |
|---|---|---|---|---|---|---|---|
| GOG-218 | Front-line and maintenance | 1873 | I: chemotherapy with placebo added in cycles 2 through 22 | 10.3 | — | 41.1 | — |
| II: chemotherapy with bevacizumab added in cycles 2 through 6 and placebo added in cycles 7 through 22 | 11.2 | 0.908 (0.795-1.040) | 40.8 | 1.06 (0.94-1.20) | |||
| III: chemotherapy with bevacizumab added in cycles 2 through 22 | 14.1 | 0.717 (0.625-0.824) | 43.4 | 0.96 (0.85-1.09) | |||
| ICON7 | Front-line and maintenance | 1528 | I: paclitaxel + carboplatin | 17.4 | 0.87 (0.77-0.99) | 44.6 | 0.99 (0.85-1.14) |
| II: paclitaxel + carboplatin + bevacizumab; bevacizumab maintenance | 19.8 | 45.5 | |||||
| OCEANS | Platinum-sensitive recurrent | 484 | I: chemotherapy (gemcitabine and carboplatin) | 8.4 | 0.484 (0.388-0.605) | 29.9 | 0.751 (0.537-1.052) |
| II: bevacizumab with chemotherapy | 12.4 | 35.5 | |||||
| AURELLA | Platinum-resistant recurrent | 361 | I: single-agent chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, and topotecan) | 3.4 | 0.48 (0.38-0.60) | 13.3 | 0.85 (0.66-1.08) |
| II: single-agent chemotherapy + bevacizumab | 6.7 | 16.6 | |||||
| GOG-213 | Recurrent, platinum-sensitive | 674 | I: paclitaxel + carboplatin | 10.4 | 0.628 (0.534-0.739) | 37.3 | 0.829 (0.683-1.005) |
| II: paclitaxel + carboplatin + bevacizumab | 13.8 | 42.2 | |||||
| AGO 2.21 | Platinum-sensitive recurrent | 682 | I: carboplatin + gemcitabine + bevacizumab; bevacizumab maintenance | 11.6 | 0.81 (0.68-0.96) | 27.8 | 0.81 (0.67-0.98) |
| II: carboplatin + pegylated liposomal doxorubicin + bevacizumab; bevacizumab maintenance | 13.3 | 31.9 | |||||
| MITO 16b | Platinum-sensitive recurrent | 406 | I: carboplatin-based doublet intravenously | 8.8 | 0.51 (0.41-0.65) | 27.1 | 0.99 (0.73-1.39) |
| II: carboplatin-based doublet plus bevacizumab | 11.8 | 26.7 |